Telix Pharmaceuticals Ltd (ASX: TLX) reported a significant milestone, achieving its full year revenue guidance with a total of US$804 million, aligning with its revised expectations of US$800 million to US$820 million. This announcement, made late yesterday, highlights the company’s robust performance, particularly in the fourth quarter, where revenues surged to US$208 million, marking a remarkable 46% increase compared to the same period last year.
In a detailed overview of its financial performance, Telix noted that its precision medicine division generated approximately US$161 million in revenue, reflecting a 4% increase from the previous quarter. This growth was largely attributed to the successful launch of Gozellix in the United States, which received backing from the Centers for Medicare and Medicaid Services (CMS) effective from October 1, 2025.
Dr Christian Behrenbruch, Managing Director of Telix, expressed satisfaction with the results, stating, “Our Precision Medicine business delivered excellent sequential growth in Q4 2025, driven in part by the successful U.S. launch of Gozellix.” He emphasized that this revenue growth outstripped the 3% increase in dose volumes, showcasing the effectiveness of their dual-product strategy in enhancing market share and pricing.
Clinical Trials and Future Prospects
On the clinical front, Telix announced the dosing of the first international patients for part 2 of the ProstACT Global Phase 3 study of its lead prostate cancer therapy candidate, TLX591-Tx. This study is now open for enrolment in Australia, New Zealand, and Canada, with plans to expand to additional sites in China, Singapore, South Korea, Turkey, the United Kingdom, and Japan, where regulatory approvals have been granted. Data from part 1 of the trial will be submitted to the U.S. Food and Drug Administration (FDA) to evaluate eligibility for U.S. patient participation in the next phase.
Additionally, Telix reported that it has commenced dosing the first U.S. patients in the Solace study, which focuses on its therapeutic candidate aimed at alleviating pain in patients suffering from osteoblastic bone metastases due to prostate and breast cancers.
In a further boost to its portfolio, Telix announced that China’s National Medical Products Administration (NMPA) has accepted a new drug application (NDA) for Illuccix, its premier prostate cancer imaging agent. This application was submitted in collaboration with its strategic partner in the Greater China region, Grand Pharmaceutical Group Limited. The NDA seeks a broad label reflecting the clinical utility of Illuccix across various stages of prostate cancer care, incorporating data from the Illuccix China Pivotal Phase 3 Registration study, which yielded positive results in December 2025.
Telix highlighted the urgent need for effective prostate cancer treatments, noting that over 134,000 men were diagnosed with the disease in 2022, with this figure increasing by approximately 6% annually. Illuccix has already received approvals from multiple regulatory agencies, including the FDA, Australia’s Therapeutic Goods Administration, the UK Medicines and Healthcare Products Regulatory Agency, and in 19 countries within the European Economic Area.
Telix Pharmaceuticals is positioning itself for continued growth in the coming years, with a strong pipeline and strategic expansions set to enhance its market presence and address critical healthcare needs.
